# EPO906 Therapy in Patients With Advanced Breast Cancer

> **NCT00035126** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 46 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** epothilone b

## Key facts

- **NCT ID:** NCT00035126
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2003-11
- **Final completion:** 2003-11
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035126, "EPO906 Therapy in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00035126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*